Real-world prevalence across 159 872 patients with cancer supports the clinical utility of TMB-H to define metastatic solid tumors for treatment with pembrolizumab
- PMID: 34082018
- DOI: 10.1016/j.annonc.2021.05.805
Real-world prevalence across 159 872 patients with cancer supports the clinical utility of TMB-H to define metastatic solid tumors for treatment with pembrolizumab
Conflict of interest statement
Disclosure DF, LA, AW, JH and PH are employees of Foundation Medicine and RC, AS, JL, DAG, FJ and ER are employees of Merck.
Comment in
-
Reply to: 'Real-world prevalence across 159 872 patients with cancer supports the clinical utility of TMB-H to define metastatic solid tumors for treatment with pembrolizumab.' by D. Fabrizio et al.Ann Oncol. 2021 Sep;32(9):1194-1197. doi: 10.1016/j.annonc.2021.06.017. Epub 2021 Jun 21. Ann Oncol. 2021. PMID: 34166757 No abstract available.
Comment on
-
High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types.Ann Oncol. 2021 May;32(5):661-672. doi: 10.1016/j.annonc.2021.02.006. Epub 2021 Mar 15. Ann Oncol. 2021. PMID: 33736924 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical